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Introduction
Gastric cancer (GC) is one of the malignant tumors of
gastrointestinal tract with the highest mortality [1].
Degradation of extracellular matrix (ECM), the physi-
cal barrier for migration of neoplastic cells into tissues,
is known as an essential step of tumor invasion,
aggressive growth and formation of metastases [2,3].
Matrix metalloproteinases (MMPs) are the enzymes
capable of degrading all the components of ECM [4].
The proteolysis of basement membranes depends on
the balance between activities of MMPs and tissue
inhibitors of metalloproteinases (TIMPs) [3]. More-
over, TIMPs play an important role in the extent of the
matrix degradation [5]. 
Enhanced tissue expression of TIMP-1 was
observed in various malignant tumors, including
gastric [6] and colorectal cancers [7]. It has been also
shown that expression of TIMP-1 in GC tissue cor-
related with tumor invasion and lymph node metas-
tasis [8]. However, little is known about expression
of TIMP-1 in interstitial inflammatory infiltrate cells
in gastric cancer. Infiltration of inflammatory cells is
a characteristic feature of many malignant tumors,
including gastric cancer. The inflammatory cells pro-
duce metalloproteinases to the peritumoral environ-
ment. These cells are also able to synthesize various
cytokines enhancing expression of MMPs and
TIMPs by both – tumoral and stromal cells [9]. 
Therefore, the aim of the current study was to
compare the intensity of TIMP-1 expression in neo-
plastic and interstitial inflammatory infiltrate cells in
gastric cancer tissue with clinico-pathological fea-
tures of tumors. According to our knowledge, this is
the first study assessing the expression of TIMP-1 in
tumor-infiltrating lymphocytes and other inflamma-
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Material and methods
Patients. Fifty-four GC patients diagnosed from April 2003 to
May 2008 and operated on in the Second General Surgery Depar-
tament, University Hospital of Bia³ystok were studied. The pri-
mary selection criteria for this study were the adequate follow-up
for tumor-specific analysis of survival and the availability of tumor
samples (formalin-fixed and parafin-embedded blocks). 
The study group included 13 women and 41 men, mean age
was 67.5 year (range 37-84 years). Clinical diagnosis of gastric
cancer was confirmed by microscopic examination of the material
obtained during surgery or endoscopy. The standard TNM (tumor,
nodulus, metastases) classification was used for staging of tumors
according to the 5th International Union Against Cancer [10]. Thir-
ty-five patients survived, whereas 19 patients died of cancer during
the observation period (1-48 months). The study was approved by
the local Ethics Committee. All the patients gave their informed
consent for the analysis. 
Immunohistochemical (IHC) staining. The tissue samples were
collected during the course of surgery, fixed in 10% buffered for-
malin, dehydrated and embedded in paraffin. For detection of
TIMP-1 expression in cancer tissue the mice monoclonal antibod-
ies against human TIMP-1 (Novocastra; clone 6F6a, dilution
1:112) were used. The visualization of antigen presence was
obtained using Novocastra Peroxidase Detection System. The
expression of TIMP-1 in gastric cancer cells as well as in inflam-
matory infiltrate cells (macrophages, polinuclears and lympho-
cytes) in the neoplastic interstitium was evaluated in the light
microscopy, using semi-quantitative scale: 0 pt – no reaction, 1 pt
– weak, 2 pts – moderate and 3 pts – intense reaction.
Statistical analysis. Data are presented as number of cases and
percent of analyzed subgroup. Comparisons between subgroups
were made using Fisher-Freeman-Halton's test [11]. Univariate
analyses of survival were performed using the log-rank test, and
multivariate analyses employed the Cox proportional hazards
model. The differences were considered as statistically significant
with p<0.05. Statistical analyses were carried out using the
STATISTICA 5.1 PL program (StatSoft Inc., Tulsa, OK). 
Results
The expression of tissue inhibitor of matrix
metalloproteinases-1 in gastric cancer cells
The positive reaction for TIMP-1 was observed in
100% of all tissue samples of gastric cancer: weak (1
pt) in 22%, moderate (2 pts) in 50% and an intense
expression (3 pts) in 28% of cases (Fig. 1). The results
of immunostaining for the presence of TIMP-1 in neo-
plastic cells in relation to clinico-pathological features
of tumor are presented in Table 1. The number of mod-
erate (2 pts) and intense reactions (3 pts) increased
with tumor stage and was the highest in stage IV (56%
and 44%, respectively). 
Similar results were observed for relationships
between the intensity of TIMP-1 expression and the
depth of tumor invasion (T factor). Number of cases
with intense expression of this protein was higher in T4
subgroup (50%) than in T2 and T3 samples (18% and
23%, respectively). Moreover, there were no weak reac-
tions in T4 subgroups (0%). The percentages of intense
expression of TIMP-1 in cancer cells increased with the
number of metastatic lymph nodes. It was observed in
6% of patients from N0 subgroup, 22% in N1, 31% of
N2 and 54% of patients from N3 subgroup. The high-
est percent of weak reaction (1 pt) was observed in N0
subgroup (44%). It was shown that expression of
TIMP-1 in cancer cells depended on the presence of
distant metastases. There were almost two times more
cases with intense reactions (42%) in the M1 sub-
group of GC samples than in the M0 samples (24%).
Moreover, there were no cases (0%) with weak inten-
sity of immunostaining in M1 subgroup in compari-
son with 29% in M0.
The intensity of TIMP-1 expression in cancer cells
correlated with survival of patients. Intense (3 pts)
expression in tumor samples from patients who died of
cancer during follow-up period was seven times higher
(63%) than in samples from patient who survived (9%). 
The mean value of TIMP-1 expressions in gastric
cancer cells were higher in more advanced stages of
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Fig. 1. TIMP-1 moderate expression in gastric cancer cells (2 pts).
Fig. 2. TIMP-1 moderate expression in inflammatory infiltrate
cells (2 pts).
tumor (2.0 in stage III and 2.44 in stage IV, respec-
tively) than in stage II (1.64). Similar results were
observed in relation to T, N and M factors as well as
for survival of patients. The differences in TIMP-1
expression intensity were statistically significant for
tumor stage, depth of tumor invasion, nodal involve-
ment and patients' survival. 
The expression of tissue inhibitor of matrix
metalloproteinases-1 in inflammatory infiltrate
cells
The expression of TIMP-1 in interstitial inflammatory
infiltrate cells (macrophages, polinuclears and lym-
phocytes) in gastric cancer samples was evaluated
using the same scale (Fig. 2). A positive reaction was
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Table 1. The expression of TIMP-1 in gastric cancer cells in relation to clinico-pathological features of tumor.
* statistically significant when p<0.05
* statistically significant when p<0.05
Table 2. The expression of TIMP-1 in interstitial inflammatory infiltrate cells in relation to clinico-pathological features of tumor.
also observed in 100% of all tissue samples: weak (1
pt) in 7%, moderate (2 pts) in 37% and an intense
expression (3 pts) in 56% of cases. 
The results of immunostaining for the presence of
TIMP-1 in inflammatory cells in relation to clinico-
pathological features of tumor are presented in Table 2.
We have shown that expression of TIMP-1 in interstitial
inflammatory infiltrate cells related to tumor stage. The
percentages of intense expression (3 pts) of TIMP-1 were
the higest in stage IV (83%) in comparison with less
advanced stages (43% in stage II and 41% in stage III). 
The differences in TIMP-1 expression in inflamma-
tory infiltrate cells in relation to depth of tumor inva-
sion (T factor) and presence of nodal metastases (N
factor) are similar to results observed in cancer cells.
The number of intense expression (3 pts) increased
with depth of tumor invasion and nodal involvement.
The intense expression was observed more frequently
in T4 subgroup (75%) than in less advanced stages
(45% in T2 and 52% in T3) and in N3 samples (92%)
in comparison with subgroup of N0 tumors (50%).
Immunostaining revealed also the relationships
between TIMP-1 expression and presence of distant
metastases (M factor). There were over two times
more cases with intense reactions (92%) in the M1
subgroup of GC samples than in M0 tumors (45%).
Moreover, we have observed no cases (0%) with weak
intensity of immunostaining in M1 subgroup in com-
parison with 10% in M0 samples.
The relationships between intensity of TIMP-1
expression in inflammatory infiltrate cells and survival
of GC patients are similar to those in cancer cells.
Intense (3 pts) expression in tumor samples from
patients who died of cancer during follow-up period
was almost three times higher (95%) than in samples
from patient who survived (34%).
The mean values of TIMP-1 were higher in inflam-
matory infiltrate (2.48) than in cancer cells (2.06). The
mean expressions of this protein in inflammatory cells
were also higher in more advanced stages of tumor
(2.41 in stage III and 2.83 in stage IV, respectively)
than in stage II (2.14). 
Similar correlations were noticed in relation to T,
N, M factors and survival of patients. The mean TIMP-
1 expression in inflammatory cells increased with
tumor size, number of lymph nodes involved and in
presence of distant metastases as well as in patients
died of cancer in comparison with those who survived.
The differences in intensity of TIMP-1 expression
were statistically significant for tumor stage, nodal
involvement, presence of distant metastases and
patients' survival. Moreover, the mean values of this
protein expression were higher in inflammatory infil-
trate cells than in all analyzed subgroups of cancer
cells. 
Correlations between TIMP-1 expresion
in cancer and inflammatory infiltrate cells
and prognosis of patients' survival
Univariate Cox's analysis showed that tumor stage in
TNM classification (p=0.009), presence of lymph
node metastases (N) (p=0.037), distant metastases (M)
(p=0.001) and TIMP-1 expression in cancer (p=0.001)
and inflammatory infiltrate cells (p=0.005) were statis-
tically significant prognostic factors for patients' sur-
vival (Table 3). Consequently, these variables were
included in the multivariate regression analysis. It was
shown in multivariate analysis that only T factor
(p=0.023) and expression of TIMP-1 in inflammatory
infiltrate cells (p=0.024) were the independent statisti-
cally significant prognostic factors affecting survival
of GC patients.
Discussion
Gastric cancer is one of the most aggressive malignant
tumors of gastrointestinal tract. It is thought that
degradation of extracellular matrix ECM might be an
essential step of invasion and metastasis of gastric
cancer. MMPs are produced by neoplastic cells and
their synthesis in cancer may be induced by cytokines
and growth factors [12]. The endogenous inhibitors of
matrix metalloproteinases inhibit the active forms of
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* statistically significant when p<0.05
Table 3. Results of Cox's univariate analysis in gastric cancer
patients.
MMPs and regulate the processes of their activation.
This provides a double negative control of tumor
development. The imbalance between MMPs, prote-
olytic enzymes capable of degrading ECM and their
inhibitors may facilitate progression of neoplastic
cells. 
High expression of TIMP-1 protein in tumor tissues
from GC patients was previously shown in several
studies [8,13]. The concentration of this protein in
tumor tissue correlated with patients' survival [14] and
more aggresive phenotype of gastric cancer [6]. The
expression of TIMP-1 in cancer tissue correlated with
clinico-pathological factors, such as depth of tumor
invasion (T), nodal metastasis (N) and recurrence of
tumor [8]. However, little is known about the relation-
ship between TIMP-1 expression in the interstitial
inflammatory infiltrate cells in gastric cancer tissue
and clinico-pathological features of tumor and
patients' survival.
In the current study, the presence of TIMP-1 in can-
cer and interstitial inflammatory infiltrate cells was
proved by immunostaining and the positive reaction in
all specimens was observed. We have shown that
TIMP-1 expression in cancer cells depended on tumor
stage. The intensity and the mean value of this protein
expression were higher in more advanced stages of GC
and increased with depth of tumor invasion and pres-
ence of lymph node and distant metastases. Our find-
ings are in agreement with results obtained by Seo et
al [8], who have shown significant correlation between
TIMP-1 expression and T and N stages in gastric car-
cinoma samples. Probably the higher expression of
TIMP-1 in patients with more advanced gastric cancer
might be related to antitumoral response of the organ-
ism and predict the aggressive behavior of gastric car-
cinoma [15]. 
In the present study, the expression of TIMP-1 in
inflammatory cells was assessed. Infiltration of
inflammatory cells is a prominent and characteristic
feature of many malignant tumors. The inflammato-
ry cells can produce metalloproteinases to the peritu-
moral environment. These cells are also able to syn-
thesize various cytokines enhancing expression of
MMPs by both – tumoral and stromal cells [9].
Intensity of TIMP-1 positive inflammatory infiltrate
(macrophages, polynuclears and lymphocytes) in the
neoplastic interstitium was evaluated in the same
score scale as in cancer cells. The positive reaction
in inflammatory infiltrate cells was observed in
100% of specimens. There was also a tendency to
increase the intensity of TIMP-1 expression in
advanced stages of tumor in comparison to early
stages.
The mean expression of TIMP-1 was higher in
inflammatory infiltrate than in cancer cells and
increased in more advanced stages of disease. This
more intense reaction in advanced stage of disease
may be the result of TIMP 1 synthesis by inflammato-
ry cells, i.e. tumor associated macrophages, polynu-
clear granulocytes and lymphocytes as well as by can-
cer cells. In cancer tissue, infiltration of inflammatory
cells has been suggested to be a mechanism of host
resistance [16]. Moreover, we observed that intensity
of TIMP-1 expression in both types of cells correlated
with patients' survival and TIMP-1 expression in
inflammatory cells was an independent, significant
prognostic factor for GC patients. 
In conclusion, this is the first study comparing the
expression of tissue inhibitor of metalloproteinases-1
in inflamatory infiltrate cells in gastric cancer tissue
with patients' survival. We proved the presence of
TIMP-1 in neoplastic and interstitial inflammatory
infiltrate cells in GC tissue and its increased intensity
in relation to tumor stage, lymph node metastases and
survival of GC patients. The higher incidence of this
protein expression in more advanced stages of GC and
its correlation with patients' survival suggest the clini-
cal usefulness of TIMP-1 expression as prognostic fac-
tor for gastric cancer patients' survival, although this
issue requires additional studies. 
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